Please login to the form below

Not currently logged in

Boehringer and Lilly sway NICE with new Jardiance data

Diabetes drug now backed to help glycaemic control in adults
Boehringer Ingelheim

Boehringer and Lilly's Jardiance (empagliflozin) has been backed by NICE as a treatment for type 2 diabetes.

The positive final appraisal decision from NICE marks a turnaround for the product, which was last year knocked back by the cost-effectiveness body for England and Wales.

In draft guidance issued in August NICE acknowledged the drug's clinical effectiveness but took issue with what it saw as a lack of data to justify Jardiance's cost.

Boehringer and Lilly said the drug has been recommended for a number of indications in type 2 diabetes, including in combination with metformin and in a triple therapy regimen in combination with metformin and a sulfonylurea.

Jardiance was also recommended for type 2 diabetes patients with metformin and a thiazolidinedione and in combination with insulin with or without other antidiabetic drug and in those who are currently receiving NHS treatment.

Dr Charlies De Wet, medical director at Boehringer Ingelheim, said: “We are very pleased that NICE has recommended empagliflozin as a clinically and cost effective treatment. It will provide an additional therapeutic option for the management of glycaemic control in people with type 2 diabetes in England.”

Jardiance (empagliflozin) is jointly marketed by Boehringer and Eli Lilly and forms part of their 2011 diabetes alliance. Approved in Europe in May last year, the drug received a US licence in August.

Article by
Kirstie Pickering

26th January 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...